Overview

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Status:
Recruiting
Trial end date:
2025-11-07
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Atridia Pty Ltd.